Plain-English translation of NCT05520255 on ClinicalTrials.gov ↗ ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new diagnostic imaging scan called PET/CT that helps doctors detect prostate cancer more accurately. The scan uses a small amount of radioactive tracer injected into your bloodstream to highlight cancer cells in your body. Researchers want to understand how well this medication works and how safe it is in different groups of prostate cancer patients.
Current imaging methods sometimes miss prostate cancer or create confusing results that are hard to interpret. This trial exists to see whether this new imaging approach can more reliably detect where cancer has spread or returned after treatment, which could help doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will receive a small injection of radioactive tracer through an IV line, then lie still in a PET/CT scanner for about 2.5 hours while it takes detailed images of your body. The research team will check you for any side effects right after the injection and again after the scan is complete. You'll be given contact information to report any delayed effects over the next week, and researchers will follow your imaging results for at least a year afterward.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
Canada